47 urothelial cancer patients WES and 38 RNAseq
We performed a global mutational landscape analysis using tumor samples from the 47 urothelial cancer patients included in MATCH-R or MOSCATO studies, with advanced metastatic disease and WES available (RNAseq is included for 38 patient samples).
- 133 samples
- DAC: EGAC00001003273
- Technologies: Illumina HiSeq 2000, Illumina HiSeq 4000, Illumina NovaSeq 6000, NextSeq 500
In accessing these datasets, you prioritize patient privacy and confidentiality. you will adhere to all applicable laws and regulations, including the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR).
As a healthcare organization committed to improving patient outcomes and advancing medical research, we recognize the importance of accessing patient sequencing files. We believe that analyzing genetic data can help identify potential health risks, develop personalized treatment plans, and inform future medical discoveries. In accessing these datasets, you prioritize patient privacy and confidentiality. you will adhere to all applicable laws and regulations, including the Health Insurance Portability and Accountability Act (HIPAA) and the General Data Protection Regulation (GDPR). You will use the data solely for research purposes, and will not disclose any patient information to third parties without explicit consent or as required by law. We recognize the importance of collaboration and open sharing of research data, and we make every effort to ensure that the data is used responsibly and ethically. You will acknowledge the contributions of all researchers and institutions involved in the collection and analysis of the data.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
Study ID | Study Title | Study Type |
---|---|---|
Cancer Genomics |